Abstracts tagged "inflammation and interferons"

Abstract Number: 975 • 2018 ACR/ARHP Annual Meeting
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
KA Casey¹, WI White¹, Nickie L. Seto², Martin Playford³, MA Smith¹, P Carlucci², B Yu⁴, L Wang⁵, G Illei⁴, Nehal Mehta³ and Mariana J. Kaplan², ¹MedImmune, Gaithersburg, MD, ²NIAMS, Bethesda, MD, ³NHLBI, Bethesda, MD, ⁴MedImmune, Gaithersberg, MD, ⁵AstraZeneca, Gaithersburg, MD
Background/Purpose: Cardiovascular disease is a leading cause of death for patients with systemic lupus erythematosus (SLE), and the disease is widely known to feature premature…
Abstract Number: 2349 • 2017 ACR/ARHP Annual Meeting
Interferon Signature in Childhood Rheumatic Diseases
Hafize Emine Sonmez¹, İ. Çağatay Karaaslan², Ezgi Deniz Batu³, Banu Anlar⁴, Betul Sozeri⁵, Adriana Almeida de Jesus⁶, Raphaela Goldbach-Mansky⁷ and Seza Ozen⁸, ¹Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Molecular Biology, Hacettepe University, Ankara, Turkey, ³Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Department of Pediatrics, Division of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Pediatric Rheumatology, Ümraniye Tranning and Research Hospital, İstanbul, Turkey, ⁶National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁷Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Several rheumatic diseases are characterized by overexpression of type I interferon(IFN)-inducible or viral response genes, termed the IFN signature. Recently this signature has been…
Abstract Number: 2875 • 2017 ACR/ARHP Annual Meeting
Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets
Judith A. James¹, Joel M. Guthridge², Hua Chen³, Rufei Lu³, Rebecka L. Bourn³, Alan N. Baer⁴, Ghaith Noaiseh⁵, Anne Parke⁶, Andreea Coca⁷, Tammy Utset⁸, Mark C. Genovese⁹, Teresa Aberle³, Daniel J. Wallace¹⁰, Karen Boyle¹¹, Lynette Keyes-Elstein¹², Nathalie Franchimont¹³, Eugene St. Clair¹⁴, Virginia Pascual¹⁵, Paul J. Utz¹⁶ and Kathy L. Sivils², ¹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶University of Connecticut, Farmington, CT, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Chicago, Chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA, ¹⁰UCLA, Beverly Hills, CA, ¹¹Rho Federal Systems, Inc, Chapel Hill, NC, ¹²Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Biogen, Cambridge, MA, ¹⁴Department of Medicine, Duke University Medical Center, Durham, NC, ¹⁵Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ¹⁶Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Immunologic heterogeneity in primary Sjogren’s syndrome (pSS) poses a challenge when selecting a therapeutic for a given patients or when assembling patient cohorts for…
Abstract Number: 1202 • 2014 ACR/ARHP Annual Meeting
Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE
Bo Qu¹, Jianchang Cao², Feifei Zhang² and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Systemic lupus erythematosus (SLE) is characterized by the uncontrolled inflammation along with over produced inflammatory cytokines, among which type I interferon (IFN) is recognized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].